Risk evaluation and monitoring in multiple sclerosis therapeutics

Conclusions:
It is difficult to produce a general risk-assessment algorithm for all MS therapies. Specific algorithms are required for each DMT in every treated-patient population. New and evolving risks must be evaluated and communicated rapidly to allow patients and physicians to be well informed and able to share treatment decisions.

Source: Multiple Sclerosis - August 26, 2014 Category: Neurology Authors: Clanet, M. C., Wolinsky, J. S., Ashton, R. J., Hartung, H.-P., Reingold, S. C. Tags: Meeting Review Source Type: research